{"id":"NCT03282227","sponsor":"Zosano Pharma Corporation","briefTitle":"A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine","officialTitle":"A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-07","primaryCompletion":"2019-05-17","completion":"2019-05-17","firstPosted":"2017-09-13","resultsPosted":"2020-08-19","lastUpdate":"2020-08-19"},"enrollment":342,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"M207 Microneedle System","otherNames":["ZP-Zolmitriptan Intracutaneous Microneedle System","ADAM-Zolmitriptan"]}],"arms":[{"label":"M207 Microneedle System 3.8 mg","type":"EXPERIMENTAL"}],"summary":"This is an open-label, twelve-month safety study. There is a screening period followed by a run-in period to record migraine activity. Qualified subjects will receive study medication for up to twelve months for the treatment of multiple migraine attacks. Using the electronic diary (eDiary) to confirm they are experiencing a qualified migraine, subjects will self-administer the patches and respond to questions in the eDiary post treatment administration.","primaryOutcome":{"measure":"Number of Subjects With Any Treatment-emergent Adverse Events (TEAE) Over 12 Months","timeFrame":"0 to 12 months","effectByArm":[{"arm":"M207 Microneedle System 3.8 mg","deltaMin":323,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States"]},"refs":{"pmids":["34001002"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":335},"commonTop":["Application site erythema","Application site swelling","Application site haemorrhage","Application site bruise","Application site pain"]}}